Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rockwell Automation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Rockwell Automation trades at $470.46 (market cap $52.53B). The key difference: Rockwell Automation is the larger of the two by market cap, and Rockwell Automation pays a 1.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ROK | |
|---|---|---|
Market Cap | $39.89B | $52.53B |
Sector | Health | Industrials |
52-Week High | $491.22 | $495.08 |
52-Week Low | $278.09 | $328.67 |
Enterprise Value | $38.15B | $56.17B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Rockwell Automation (ROK) trades at $472.12, up 0.99% on the day, showing strong momentum with three consecutive earnings beats. The stock's technical picture is neutral with bullish moving averages, while valuation multiples remain elevated with a P/E of 49.03. Recent news highlights the company's leadership in industrial automation and AI infrastructure growth potential, with multiple Zacks recognition as a top momentum and growth stock in July 2026.
ROK presents a mixed outlook with strong operational cash flow and recent earnings outperformance offset by premium valuations. Investment opportunity lies in industrial automation growth and AI infrastructure tailwinds, while risks include competitive pressures and sensitivity to industrial spending cycles. Analyst consensus leans cautious with 64% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
